ANI Pharmaceuticals
ANIP
281 hedge funds and large institutions have $1.8B invested in ANI Pharmaceuticals in 2026 Q1 according to their latest regulatory filings, with 46 funds opening new positions, 110 increasing their positions, 83 reducing their positions, and 45 closing their positions.
200% more funds holding in top 10
Funds holding in top 10: 1 → 3 (+2)
33% more repeat investments, than reductions
Existing positions increased: 110 | Existing positions reduced: 83
10.12% more ownership
Funds ownership: 94.26% → 104.38% (+10%)
8% more capital invested
Capital invested by funds: $1.67B → $1.8B (+$127M)
2% more first-time investments, than exits
New positions opened: 46 | Existing positions closed: 45
1% less funds holding
Funds holding: 284 → 281 (-3)
51% less call options, than puts
Call options by funds: $15.6M | Put options by funds: $32.1M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GAM
Goldentree Asset Management
New York
|
+$52.1M |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$27.1M |
| 3 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
+$26.1M |
| 4 |
TCM
Tang Capital Management
San Diego,
California
|
+$17.6M |
| 5 |
SCM
Sio Capital Management
New York
|
+$13.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GACM
Global Alpha Capital Management
Montreal,
Quebec, Canada
|
-$17.9M |
| 2 |
Balyasny Asset Management
Chicago,
Illinois
|
-$16.2M |
| 3 |
ACA
Apis Capital Advisors
New York
|
-$15.5M |
| 4 |
Goldman Sachs
New York
|
-$14.1M |
| 5 |
BNP Paribas Financial Markets
Paris,
France
|
-$10.1M |
ANIP Hedge Fund Activity: Q1 2026 in Review
281 of the 8,187 institutional investors tracked by Wall St. Rank reported a position in ANI Pharmaceuticals (ANIP) for Q1 2026, worth a combined $1.8B — up 7.6% from $1.67B a quarter earlier.
Buyers outnumbered sellers: 46 funds opened new ANIP positions and 45 closed out — a net gain of 1 holder — while 110 added to existing stakes and 83 trimmed.
The largest buyer was Goldentree Asset Management, opening a new position worth an estimated $52.1M. The largest seller was Global Alpha Capital Management, cutting an estimated $17.9M.
- 281 institutional investors held ANI Pharmaceuticals (ANIP) as of Q1 2026, down from 284 in Q4 2025.
- Funds reported $1.8B of ANI Pharmaceuticals stock for Q1 2026, up 7.6% quarter-over-quarter.
- 46 funds opened new ANI Pharmaceuticals positions in Q1 2026 and 45 closed out, a net change of +1 holder.
- The largest ANI Pharmaceuticals buyer in Q1 2026 was Goldentree Asset Management, an estimated $52.1M added.
- The largest ANI Pharmaceuticals seller in Q1 2026 was Global Alpha Capital Management, an estimated $17.9M sold.
Based on aggregated 13F filings for Q1 2026.